MCID: ANP031
MIFTS: 64

Anaplastic Thyroid Cancer

Categories: Cancer diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Anaplastic Thyroid Cancer

MalaCards integrated aliases for Anaplastic Thyroid Cancer:

Name: Anaplastic Thyroid Cancer 53
Anaplastic Thyroid Carcinoma 53 59 6 73
Thyroid Carcinoma, Anaplastic 53
Thyroid Carcinoma Anaplastic 55
Thyroid Cancer, Anaplastic 53

Characteristics:

Orphanet epidemiological data:

59
anaplastic thyroid carcinoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Adult;

Classifications:

Orphanet: 59  
Rare endocrine diseases


Summaries for Anaplastic Thyroid Cancer

NIH Rare Diseases : 53 Anaplastic thyroid cancer(ATC) accounts for less than 2% of all thyroid cancers and is the most aggressive type of thyroid cancer. Most cases of anaplastic thyroid cancer are diagnosed in the sixth to seventh decade of life. Women are more likely to be affected than men. ATC generally occurs in individuals with a history of goiter or thyroid cancer. A history of head and neck radiation or exposure to radioactive materials may also increase the risk for ATC. Patients with ATC generally present with a rapidly-growing neck mass which may cause trouble swallowing (dysphagia), coughing, neck pain, and trouble breathing (dyspnea).Metastasis is present in more than half of individuals at the time of diagnosis. Patients with metastases may also present with bone pain, lymph node enlargement, weakness, and neurological deficits. Treatment of ATC is mostly palliative.

MalaCards based summary : Anaplastic Thyroid Cancer, also known as anaplastic thyroid carcinoma, is related to thyroid cancer and goiter, and has symptoms including dyspnea and hoarseness. An important gene associated with Anaplastic Thyroid Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and Cytokine Signaling in Immune system. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include thyroid, bone and lymph node, and related phenotypes are dysphonia and dysphagia

Wikipedia : 76 Anaplastic thyroid cancer (ATC) is a form of thyroid cancer which has a very poor prognosis due to its... more...

Related Diseases for Anaplastic Thyroid Cancer

Diseases related to Anaplastic Thyroid Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 178)
# Related Disease Score Top Affiliating Genes
1 thyroid cancer 30.4 BRAF CASP3 CDH1 CDKN1A CTNNB1 EGF
2 goiter 30.2 NKX2-1 PAX8 TG TPO
3 multinodular goiter 30.2 NKX2-1 PAX8 TG TPO
4 papillary thyroid microcarcinoma 30.0 BRAF MET NKX2-1 TG
5 differentiated thyroid carcinoma 29.8 BRAF EGF MET NKX2-1 PAX8 TG
6 adenocarcinoma 29.6 BRAF CDH1 CTNNB1 EGF PIK3CA PTEN
7 papillary carcinoma 29.5 BRAF CDH1 MET NKX2-1 PAX8 TG
8 melanoma 29.4 BRAF MIR19A MIR34C PTEN TP53
9 thyroid hurthle cell adenoma 10.3 PIK3CA PTEN
10 nevus of ota 10.3 BRAF TP53
11 rare adenocarcinoma of the breast 10.3 PIK3CA TP53
12 subacute lymphocytic thyroiditis 10.3 TG TPO
13 pharynx squamous cell carcinoma 10.3 CASP3 PTEN
14 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.3 PIK3CA PTEN TP53
15 thyroid cancer, nonmedullary, 1 10.3
16 short-rib thoracic dysplasia 4 with or without polydactyly 10.3 CASP3 TP53
17 mature teratoma 10.2 BRAF TG TP53
18 brain stem glioma 10.2 BRAF PIK3CA TP53
19 giant cell glioblastoma 10.2 BRAF PTEN TP53
20 ovarian clear cell carcinoma 10.2 PIK3CA PTEN TP53
21 malignant spiradenoma 10.2 PIK3CA TP53
22 breast cystic hypersecretory carcinoma 10.2 CDH1 TG
23 struma ovarii 10.2 BRAF NKX2-1 TG
24 familial thyroid dyshormonogenesis 10.2 TG TPO
25 ovarian serous cystadenocarcinoma 10.2 BRAF PIK3CA TP53
26 colloid adenoma 10.2 NKX2-1 TG TP53
27 adenosquamous carcinoma 10.2 NKX2-1 PIK3CA TP53
28 atypical follicular adenoma 10.2 CDKN1A TG TP53
29 small cell carcinoma 10.2 NKX2-1 PTEN TP53
30 prostate transitional cell carcinoma 10.2 CTNNB1 PIK3CA
31 cerebral convexity meningioma 10.2 CDH1 TP53
32 urinary tract obstruction 10.2 CDH1 EGF PIK3CA
33 ovarian germ cell teratoma 10.2 NKX2-1 TG
34 testicular germ cell tumor 10.2 BRAF PTEN TP53
35 actinic cheilitis 10.2 CDKN1A TP53
36 papillary adenocarcinoma 10.2 CDH1 NKX2-1 TP53
37 female reproductive endometrioid cancer 10.2 CTNNB1 PTEN TP53
38 athyreosis 10.2 NKX2-1 PAX8 TG
39 neonatal hypothyroidism 10.2 PAX8 TG TPO
40 spinal chordoma 10.2 MET PIK3CA TERT
41 hypothyroidism, congenital, nongoitrous, 2 10.2 NKX2-1 PAX8 TG
42 sarcomatoid renal cell carcinoma 10.2 CDH1 PAX8 PTEN
43 supratentorial cancer 10.2 CASP3 PTEN TERT TP53
44 oral cancer 10.2 CASP3 CDH1 TP53
45 cerebrum cancer 10.2 CASP3 PTEN TERT TP53
46 childhood hepatocellular carcinoma 10.2 CTNNB1 MET
47 bladder disease 10.2 CDH1 TERT TP53
48 goiter, multinodular 1, with or without sertoli-leydig cell tumors 10.2 TG TPO
49 laryngeal squamous cell carcinoma 10.2 CDH1 TERT TP53
50 skin melanoma 10.2 BRAF CASP3 CDKN1A TP53

Graphical network of the top 20 diseases related to Anaplastic Thyroid Cancer:



Diseases related to Anaplastic Thyroid Cancer

Symptoms & Phenotypes for Anaplastic Thyroid Cancer

Human phenotypes related to Anaplastic Thyroid Cancer:

59 32 (show all 24)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dysphonia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001618
2 dysphagia 59 32 frequent (33%) Frequent (79-30%) HP:0002015
3 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
4 respiratory distress 59 32 frequent (33%) Frequent (79-30%) HP:0002098
5 broad neck 59 32 hallmark (90%) Very frequent (99-80%) HP:0000475
6 vocal cord paralysis 59 32 frequent (33%) Frequent (79-30%) HP:0001605
7 hemoptysis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002105
8 pain 59 32 frequent (33%) Frequent (79-30%) HP:0012531
9 cough 59 32 occasional (7.5%) Occasional (29-5%) HP:0012735
10 hoarse voice 59 32 hallmark (90%) Very frequent (99-80%) HP:0001609
11 tracheoesophageal fistula 59 32 very rare (1%) Very rare (<4-1%) HP:0002575
12 neoplasm of the lung 59 32 frequent (33%) Frequent (79-30%) HP:0100526
13 lymphadenopathy 59 32 frequent (33%) Frequent (79-30%) HP:0002716
14 upper airway obstruction 59 32 frequent (33%) Frequent (79-30%) HP:0002781
15 stridor 59 32 occasional (7.5%) Occasional (29-5%) HP:0010307
16 neoplasm of the skeletal system 59 32 occasional (7.5%) Occasional (29-5%) HP:0010622
17 nodular goiter 59 32 hallmark (90%) Very frequent (99-80%) HP:0005994
18 malignant neoplasm of the central nervous system 59 32 very rare (1%) Very rare (<4-1%) HP:0100836
19 anaplastic thyroid carcinoma 59 32 obligate (100%) Obligate (100%) HP:0011779
20 laryngotracheal stenosis 59 32 frequent (33%) Frequent (79-30%) HP:0004894
21 dyspnea 59 Occasional (29-5%)
22 goiter 59 Very frequent (99-80%)
23 abnormality of muscle morphology 59 Occasional (29-5%)
24 abnormal muscle morphology 32 occasional (7.5%) HP:0011805

UMLS symptoms related to Anaplastic Thyroid Cancer:


dyspnea, hoarseness

GenomeRNAi Phenotypes related to Anaplastic Thyroid Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.35 BRAF CTNNB1 ILK MET PIK3CA
2 Increased cell death HMECs cells GR00103-A-0 9.1 CASP3 CTNNB1 ILK PIK3CA PTEN TP53

MGI Mouse Phenotypes related to Anaplastic Thyroid Cancer:

46 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.49 BRAF CASP3 CDH1 CDKN1A CTNNB1 EGF
2 endocrine/exocrine gland MP:0005379 10.47 BRAF CASP3 CDH1 CDKN1A CTNNB1 EGF
3 homeostasis/metabolism MP:0005376 10.44 BRAF CASP3 CDH1 CDKN1A CTNNB1 ILK
4 cellular MP:0005384 10.43 BRAF CASP3 CDH1 CDKN1A CTNNB1 ILK
5 digestive/alimentary MP:0005381 10.42 BRAF CASP3 CDH1 CDKN1A CTNNB1 EGF
6 cardiovascular system MP:0005385 10.4 BRAF CASP3 CDH1 CDKN1A CTNNB1 ILK
7 immune system MP:0005387 10.4 BRAF CASP3 CDH1 CDKN1A CTNNB1 EGF
8 behavior/neurological MP:0005386 10.37 BRAF CASP3 CDKN1A CTNNB1 ILK MET
9 mortality/aging MP:0010768 10.37 BRAF CASP3 CDH1 CDKN1A CTNNB1 ILK
10 embryo MP:0005380 10.3 BRAF CDH1 CDKN1A CTNNB1 ILK MET
11 craniofacial MP:0005382 10.26 BRAF CASP3 CDKN1A CTNNB1 ILK MET
12 nervous system MP:0003631 10.26 BRAF CASP3 CDKN1A CTNNB1 MET NKX2-1
13 integument MP:0010771 10.25 BRAF CASP3 CDH1 CDKN1A CTNNB1 EGF
14 limbs/digits/tail MP:0005371 10.19 BRAF CDKN1A CTNNB1 MET PAX8 PTEN
15 neoplasm MP:0002006 10.19 BRAF CDH1 CDKN1A CTNNB1 MET NKX2-1
16 normal MP:0002873 10.17 BRAF CDH1 CTNNB1 EGF ILK MET
17 muscle MP:0005369 10.16 BRAF CASP3 CDKN1A CTNNB1 ILK MET
18 no phenotypic analysis MP:0003012 10.16 CASP3 CDH1 CDKN1A CTNNB1 ILK MET
19 hearing/vestibular/ear MP:0005377 10.12 BRAF CASP3 CDKN1A CTNNB1 PAX8 TP53
20 reproductive system MP:0005389 10.1 BRAF CASP3 CDH1 CDKN1A CTNNB1 EGF
21 renal/urinary system MP:0005367 10.02 BRAF CASP3 CDKN1A CTNNB1 ILK MET
22 skeleton MP:0005390 9.97 BRAF CASP3 CDKN1A CTNNB1 ILK NKX2-1
23 respiratory system MP:0005388 9.96 BRAF CASP3 CDKN1A CTNNB1 ILK MET
24 pigmentation MP:0001186 9.88 BRAF CASP3 CTNNB1 ILK PTEN TP53
25 vision/eye MP:0005391 9.36 BRAF CASP3 CDKN1A CTNNB1 EGF MET
26 taste/olfaction MP:0005394 9.26 CASP3 CTNNB1 PTEN TERT

Drugs & Therapeutics for Anaplastic Thyroid Cancer

Drugs for Anaplastic Thyroid Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1 33069-62-4 36314
2
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1 41575-94-4 10339178 38904 498142
3 Combretastatin Investigational Phase 2, Phase 3,Phase 3,Phase 1 82855-09-2
4
Fosbretabulin Investigational Phase 2, Phase 3,Phase 3,Phase 1 222030-63-9 5351387
5 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
6 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
7 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
8
leucovorin Approved Phase 2 58-05-9 6006 143
9
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843
10
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
11
Everolimus Approved Phase 2 159351-69-6 6442177
12
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
13
Cisplatin Approved Phase 1, Phase 2,Phase 2 15663-27-1 2767 441203 84093
14
Fluorouracil Approved Phase 2 51-21-8 3385
15
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
16
Hydroxyurea Approved Phase 2 127-07-1 3657
17
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
18
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
19
Iodine Approved, Investigational Phase 2,Not Applicable 7553-56-2 807
20
Gefitinib Approved, Investigational Phase 2,Not Applicable 184475-35-2 123631
21
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
22
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
23
Tamoxifen Approved Phase 2 10540-29-1 2733526
24
Vemurafenib Approved Phase 2 918504-65-1 23252090 42611257
25
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
26
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
27 tannic acid Approved Phase 2
28
Lenvatinib Approved, Investigational Phase 2 417716-92-8
29
Pembrolizumab Approved Phase 2 1374853-91-4
30
Ceritinib Approved Phase 2 1032900-25-6
31
Bevacizumab Approved, Investigational Phase 2 216974-75-3
32
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
33
Nivolumab Approved Phase 2 946414-94-4
34
Trametinib Approved Phase 2,Early Phase 1 871700-17-3 11707110
35
Docetaxel Approved, Investigational Phase 2,Phase 1 114977-28-5 148124
36
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
38
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
39
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
40
Efatutazone Investigational Phase 1, Phase 2,Phase 2 223132-37-4
41
Doxil Approved June 1999 Phase 2,Phase 1 31703
42 Folic Acid Antagonists Phase 2
43 Nucleic Acid Synthesis Inhibitors Phase 2
44 Vitamin B Complex Phase 2
45 Folate Phase 2
46 Vitamin B9 Phase 2
47 Immunosuppressive Agents Phase 2
48 Anti-Bacterial Agents Phase 2,Phase 1
49 Antifungal Agents Phase 2
50 Immunologic Factors Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 52)
# Name Status NCT ID Phase Drugs
1 Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer Terminated NCT00507429 Phase 2, Phase 3 CA4P;paclitaxel;carboplatin
2 Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer Withdrawn NCT01701349 Phase 3 Fosbretabulin + paclitaxel + carboplatin;Placebo + paclitaxel + carboplatin
3 Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer Unknown status NCT00786552 Phase 2 pemetrexed + paclitaxel
4 Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer Unknown status NCT01118065 Phase 2 everolimus
5 A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) Completed NCT01240590 Phase 1, Phase 2 Crolibulin;Cisplatin
6 A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Completed NCT00603941 Phase 1, Phase 2 CS7017;Paclitaxel
7 Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer Completed NCT00060242 Phase 2 fosbretabulin disodium
8 Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer Completed NCT00004089 Phase 2 fluorouracil;hydroxyurea;paclitaxel
9 Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients Completed NCT02114658 Phase 2 Sorafenib (Nexavar,BAY43-9006)
10 Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer Completed NCT00654238 Phase 2 sorafenib
11 Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer Completed NCT01164176 Phase 2 everolimus
12 Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy Completed NCT00095836 Phase 2 Gefitinib
13 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
14 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
15 A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers Completed NCT01524978 Phase 2 cetuximab;vemurafenib;vemurafenib
16 A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer Recruiting NCT02244463 Phase 2 MLN0128
17 Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer Recruiting NCT02726503 Phase 2 Lenvatinib
18 Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer Recruiting NCT03565536 Phase 2 Nexavar
19 Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Recruiting NCT02688608 Phase 2 Pembrolizumab
20 Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer Recruiting NCT02289144 Phase 2 Ceritinib
21 Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas Recruiting NCT03181100 Phase 2 Nab-paclitaxel - INDUCTION COHORT;Paclitaxel - INDUCTION COHORT;Vemurafenib - COHORT 1;Cobimetinib - COHORT 1;Atezolizumab - COHORT 1;Bevacizumab - COHORT 3;Nab-paclitaxel - COHORT 4;Paclitaxel - COHORT 4;Cobimetinib - COHORT 2;Atezolizumab - COHORT 2;Atezolizumab - COHORT 3;Atezolizumab - COHORT 4
22 Nivolumab Plus Ipilimumab in Thyroid Cancer Recruiting NCT03246958 Phase 2 Nivolumab;Ipilimumab
23 A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting Recruiting NCT02041260 Phase 2 Cabozantinib
24 Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer Active, not recruiting NCT02152137 Phase 2 efatutazone;paclitaxel
25 Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer Active, not recruiting NCT03211117 Phase 2 Docetaxel;Doxorubicin Hydrochloride
26 Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer Active, not recruiting NCT01236547 Phase 2 Paclitaxel;Pazopanib Hydrochloride
27 Phase I/II Study of PDR001 in Patients With Advanced Malignancies Active, not recruiting NCT02404441 Phase 1, Phase 2
28 Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Active, not recruiting NCT02034110 Phase 2 Dabrafenib;Trametinib
29 Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer Active, not recruiting NCT00625846 Phase 2 Pazopanib Hydrochloride
30 A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) Terminated NCT02657369 Phase 2 Lenvatinib 24 mg
31 Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma Terminated NCT00115739 Phase 2 Imatinib
32 Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer Terminated NCT00804830 Phase 2 Bevacizumab
33 Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer Terminated NCT00126568 Phase 2 sorafenib tosylate
34 Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer Terminated NCT00077103 Phase 1, Phase 2 cisplatin;doxorubicin hydrochloride;fosbretabulin disodium
35 CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer Terminated NCT03002623 Phase 2 CUDC-907
36 Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer Terminated NCT00095693 Phase 2 sorafenib tosylate
37 Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. Terminated NCT02012231 Phase 1, Phase 2 PLX8394
38 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
39 SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck Completed NCT00005647 Phase 1 paclitaxel;semaxanib
40 NGR-TNF in Treating Patients With Advanced Solid Tumors Completed NCT00098943 Phase 1
41 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
42 Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases Completed NCT00062348 Phase 1 boronophenylalanine-fructose complex;sodium borocaptate
43 Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer Recruiting NCT03122496 Phase 1 durvalumab;tremelimumab
44 A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers Withdrawn NCT02516774 Phase 1 Adalimumab
45 S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors Withdrawn NCT00937417 Phase 1 docetaxel;vandetanib
46 Review of Multimodality Management of Anaplastic Thyroid Cancer Completed NCT00280852
47 Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer Completed NCT00068497 Not Applicable gefitinib
48 interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT) Recruiting NCT01774279
49 Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer Recruiting NCT03085056 Early Phase 1 Trametinib;Paclitaxel
50 Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3 Recruiting NCT03488134

Search NIH Clinical Center for Anaplastic Thyroid Cancer

Genetic Tests for Anaplastic Thyroid Cancer

Anatomical Context for Anaplastic Thyroid Cancer

MalaCards organs/tissues related to Anaplastic Thyroid Cancer:

41
Thyroid, Bone, Lymph Node, Lung, Endothelial, Colon, Breast

Publications for Anaplastic Thyroid Cancer

Articles related to Anaplastic Thyroid Cancer:

(show top 50) (show all 868)
# Title Authors Year
1
Sphingosine 1-phosphate attenuates MMP2 and MMP9 in human anaplastic thyroid cancer C643 cells: Importance of S1P2. ( 29734379 )
2018
2
CRISPR/Cas9 Genome Editing of Epidermal Growth Factor Receptor Sufficiently Abolished Oncogenicity in Anaplastic Thyroid Cancer. ( 29849821 )
2018
3
Combined Effects of Baicalein and Docetaxel on Apoptosis in 8505c Anaplastic Thyroid Cancer Cells via Downregulation of the ERK and Akt/mTOR Pathways. ( 29589394 )
2018
4
Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming. ( 29534964 )
2018
5
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo. ( 29517106 )
2018
6
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. ( 29517103 )
2018
7
miR-27b-3p is Involved in Doxorubicin resistance of Human Anaplastic Thyroid Cancer Cells via Targeting PPARI^. ( 29924913 )
2018
8
A Case of Pneumothorax after Treatment with Lenvatinib for Anaplastic Thyroid Cancer with Lung Metastasis. ( 29796324 )
2018
9
Bromodomaina89containing proteinA 4 is critical for the antiproliferative and proa89apoptotic effects of gambogic acid in anaplastic thyroid cancer. ( 29717765 )
2018
10
A Synergistic Anti-Cancer Effect of Troglitazone and Lovastatin in a Human Anaplastic Thyroid Cancer Cell Line and in a Mouse Xenograft Model. ( 29932104 )
2018
11
Resveratrol Suppresses the Growth and Enhances Retinoic Acid Sensitivity of Anaplastic Thyroid Cancer Cells. ( 29596381 )
2018
12
Treatment and survival vary by race/ethnicity in patients with anaplastic thyroid cancer. ( 29409119 )
2018
13
Identification of BAG3 target proteins in anaplastic thyroid cancer cells by proteomic analysis. ( 29487711 )
2018
14
Anti-<i>hTERT</i> siRNA-Loaded Nanoparticles Block the Growth of Anaplastic Thyroid Cancer Xenograft. ( 29563163 )
2018
15
Remarkable Presentation: Anaplastic Thyroid Carcinoma Arising from Chronic Hyperthyroidism. ( 29805818 )
2018
16
Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer. ( 29774792 )
2018
17
LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway. ( 29561707 )
2018
18
Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer. ( 29487290 )
2018
19
A dual mechanism of activation of the Sonic Hedgehog pathway in anaplastic thyroid cancer: crosstalk with RAS-BRAF-MEK pathway and ligand secretion by tumor stroma. ( 29435119 )
2018
20
Dual effects for lovastatin in anaplastic thyroid cancer: the pivotal effect of transketolase (TKT) on lovastatin and tumor proliferation. ( 29502067 )
2018
21
Epigenetic modifications in poorly differentiated and anaplastic thyroid cancer. ( 28552796 )
2018
22
CCL2 is Modulated by Cytokines and PPAR-γ in Anaplastic Thyroid Cancer. ( 28730964 )
2018
23
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. ( 29072975 )
2018
24
Effects of nutraceuticals on anaplastic thyroid cancer cells. ( 29197967 )
2018
25
Digitalislike Compounds Restore hNIS Expression and Iodide Uptake Capacity in Anaplastic Thyroid Cancer. ( 29242405 )
2018
26
Effects of HuR downregulation on anaplastic thyroid cancer cells. ( 29285201 )
2018
27
Sulforaphene Enhances The Efficacy of Photodynamic Therapy In Anaplastic Thyroid Cancer Through Ras/RAF/MEK/ERK Pathway Suppression. ( 29331658 )
2018
28
Anaplastic Thyroid Cancer With Extensive Skeletal Muscle Metastases on 18F-FDG PET/CT. ( 29356736 )
2018
29
Treatment outcomes of radiotherapy for anaplastic thyroid cancer. ( 29983030 )
2018
30
Long noncoding RNA UCA1 promotes anaplastic thyroid cancer cell proliferation via miR‑135a‑mediated c‑myc activation. ( 30015867 )
2018
31
Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells. ( 30021550 )
2018
32
Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction. ( 30023346 )
2018
33
Expression of vascular endothelial growth factor receptor 2 and clinical response to lenvatinib in patients with anaplastic thyroid cancer. ( 30051190 )
2018
34
Correlation of Reactive Oxygen Species Levels with Resveratrol Sensitivities of Anaplastic Thyroid Cancer Cells. ( 30116486 )
2018
35
Hypericin-assisted photodynamic therapy against anaplastic thyroid cancer. ( 30118906 )
2018
36
Combined effects of octreotide and cisplatin on the proliferation of side population cells from anaplastic thyroid cancer cell lines. ( 30128025 )
2018
37
MicroRNA 483-3p targets Pard3 to potentiate TGF-β1-induced cell migration, invasion, and epithelial-mesenchymal transition in anaplastic thyroid cancer cells. ( 30171257 )
2018
38
The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines. ( 30191474 )
2018
39
New Optical Imaging Reporter-labeled Anaplastic Thyroid Cancer-Derived Extracellular Vesicles as a Platform for In Vivo Tumor Targeting in a Mouse Model. ( 30201988 )
2018
40
Effects of metformin on the PI3K/AKT/FOXO1 pathway in anaplastic thyroid Cancer cell lines. ( 30242671 )
2018
41
Dysfunction of natural killer cells mediated by PD-1 and Tim-3 pathway in anaplastic thyroid cancer. ( 30243069 )
2018
42
PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer. ( 30243708 )
2018
43
Antiproliferative effects of cynaropicrin on anaplastic thyroid cancer cells. ( 30264682 )
2018
44
Emodin suppresses angiogenesis and metastasis in anaplastic thyroid cancer by affecting TRAF6‑mediated pathways in vivo and in vitro. ( 30272291 )
2018
45
Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer. ( 30301881 )
2018
46
Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer. ( 30327563 )
2018
47
Therapeutic advances in anaplastic thyroid cancer: a current perspective. ( 30352606 )
2018
48
A giant mass in the neck of a young men: a case of anaplastic thyroid cancer. ( 30374397 )
2018
49
Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models. ( 30419054 )
2018
50
Overexpression of RYBP inhibits proliferation, invasion, and chemoresistance to cisplatin in anaplastic thyroid cancer cells via the EGFR pathway. ( 30431689 )
2018

Variations for Anaplastic Thyroid Cancer

ClinVar genetic disease variations for Anaplastic Thyroid Cancer:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
2 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802

Copy number variations for Anaplastic Thyroid Cancer from CNVD:

7 (show all 18)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 18562 1 146514610 148102224 Gain Anaplastic thyroid cancer
2 57418 11 63321142 66212707 Gain CCND1 Anaplastic thyroid cancer
3 68082 12 47384342 48639263 Gain Anaplastic thyroid cancer
4 78984 13 61113549 63481793 Loss Anaplastic thyroid cancer
5 99673 16 28082639 28922556 Gain Anaplastic thyroid cancer
6 114238 17 45949240 46466966 Gain Anaplastic thyroid cancer
7 124653 19 11950033 12150103 Gain Anaplastic thyroid cancer
8 128382 19 40542097 41211643 Gain Anaplastic thyroid cancer
9 152529 20 31497814 33184582 Gain Anaplastic thyroid cancer
10 153944 20 41887694 44153298 Gain UBCH10 Anaplastic thyroid cancer
11 161614 22 19538297 19939137 Gain Anaplastic thyroid cancer
12 164302 22 36003989 36444264 Gain Anaplastic thyroid cancer
13 171639 3 170900000 182700000 Copy number PIK3CA Anaplastic thyroid cancer
14 182004 4 132076562 133123563 Loss Anaplastic thyroid cancer
15 188265 4 61317501 66095641 Loss Anaplastic thyroid cancer
16 211600 6 33165527 33494594 Gain Anaplastic thyroid cancer
17 225370 7 45400000 54000000 Amplification EGFR Anaplastic thyroid cancer
18 227803 7 72035816 72259198 Gain Anaplastic thyroid cancer

Expression for Anaplastic Thyroid Cancer

Search GEO for disease gene expression data for Anaplastic Thyroid Cancer.

Pathways for Anaplastic Thyroid Cancer

Pathways related to Anaplastic Thyroid Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.91 BRAF CASP3 CDH1 CDKN1A CTNNB1 EGF
2
Show member pathways
13.4 BRAF CASP3 CDKN1A EGF MET PIK3CA
3
Show member pathways
13.16 CDKN1A EGF MET PIK3CA PTEN TP53
4
Show member pathways
13.1 CASP3 CDKN1A CTNNB1 PIK3CA PTEN TP53
5
Show member pathways
13.05 BRAF CASP3 CDH1 CTNNB1 MET TP53
6
Show member pathways
13 CASP3 CDKN1A CTNNB1 PIK3CA PTEN TP53
7
Show member pathways
13 CASP3 CDKN1A CTNNB1 EGF MET PIK3CA
8
Show member pathways
12.95 BRAF EGF ILK MET PIK3CA PTEN
9
Show member pathways
12.94 BRAF CTNNB1 EGF ILK MET MIR34C
10 12.81 BRAF CASP3 EGF MET TP53
11
Show member pathways
12.8 BRAF CDH1 CDKN1A EGF MET PIK3CA
12
Show member pathways
12.78 BRAF CDH1 CTNNB1 EGF MET PIK3CA
13
Show member pathways
12.77 CDKN1A EGF MET PIK3CA PTEN TP53
14
Show member pathways
12.73 BRAF CASP3 CDH1 CTNNB1 MET PIK3CA
15
Show member pathways
12.64 BRAF CASP3 CDH1 CDKN1A CTNNB1 EGF
16
Show member pathways
12.62 BRAF CDH1 CDKN1A CTNNB1 EGF MET
17
Show member pathways
12.55 BRAF MET PIK3CA PTEN TP53
18
Show member pathways
12.55 BRAF CDKN1A EGF MET PIK3CA TP53
19
Show member pathways
12.52 BRAF CASP3 CDH1 CTNNB1 EGF ILK
20
Show member pathways
12.5 CASP3 CTNNB1 MET PIK3CA TP53
21 12.48 CDKN1A CTNNB1 PIK3CA TERT TP53
22
Show member pathways
12.45 BRAF CDH1 CTNNB1 EGF MET PIK3CA
23
Show member pathways
12.45 CDKN1A MET PIK3CA PTEN TP53
24
Show member pathways
12.44 CASP3 CDKN1A MIR18A MIR19A PTEN TP53
25 12.33 CASP3 CDKN1A PIK3CA TP53
26 12.33 CASP3 CDKN1A PIK3CA TP53
27 12.3 BRAF CASP3 CDKN1A CTNNB1 MET PIK3CA
28 12.29 CDKN1A MET PAX8 TP53
29
Show member pathways
12.29 CASP3 CDKN1A PTEN TP53
30 12.21 CDKN1A PIK3CA PTEN TP53
31
Show member pathways
12.2 CDKN1A CTNNB1 EGF PIK3CA PTEN
32 12.2 BRAF CASP3 CDH1 CTNNB1 PTEN TP53
33
Show member pathways
12.17 BRAF CDKN1A EGF PIK3CA PTEN
34 12.13 BRAF CDKN1A EGF PIK3CA TP53
35 12.13 BRAF CASP3 CDH1 CDKN1A CTNNB1 EGF
36 12.13 CASP3 CDKN1A MET MIR18A MIR19A MIR30D
37
Show member pathways
12.12 CDH1 CDKN1A EGF MET PIK3CA
38 12.12 CDKN1A MET TERT TP53
39 12.12 BRAF CASP3 CDH1 CDKN1A CTNNB1 EGF
40 12.11 CDKN1A MET PTEN TP53
41
Show member pathways
12.11 BRAF CASP3 CDKN1A ILK MET PIK3CA
42 12.1 CASP3 CDKN1A ILK MET PIK3CA PTEN
43 12.06 CDKN1A CTNNB1 PIK3CA PTEN TP53
44 12.01 BRAF CDKN1A PTEN TP53
45 12 BRAF CDKN1A CTNNB1 EGF PTEN TP53
46 11.99 BRAF CASP3 CDH1 EGF
47
Show member pathways
11.98 BRAF CASP3 CDH1 EGF
48 11.94 CASP3 CDKN1A PIK3CA PTEN TP53
49
Show member pathways
11.92 CDH1 CTNNB1 EGF MET
50 11.9 BRAF CASP3 CTNNB1

GO Terms for Anaplastic Thyroid Cancer

Cellular components related to Anaplastic Thyroid Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 flotillin complex GO:0016600 8.96 CDH1 CTNNB1
2 lamellipodium GO:0030027 8.92 CDH1 CTNNB1 ILK PIK3CA

Biological processes related to Anaplastic Thyroid Cancer according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.97 CTNNB1 ILK MET PTEN TP53
2 MAPK cascade GO:0000165 9.9 BRAF EGF ILK MET
3 response to drug GO:0042493 9.89 CASP3 CDH1 CDKN1A CTNNB1 PTEN
4 positive regulation of transcription, DNA-templated GO:0045893 9.87 CDH1 CTNNB1 EGF ILK NKX2-1 PAX8
5 positive regulation of protein kinase B signaling GO:0051897 9.86 EGF ILK MET PIK3CA
6 positive regulation of gene expression GO:0010628 9.85 BRAF CTNNB1 EGF NKX2-1 PTEN TP53
7 negative regulation of neuron apoptotic process GO:0043524 9.81 BRAF ILK PIK3CA TERT
8 canonical Wnt signaling pathway GO:0060070 9.78 CTNNB1 EGF PTEN
9 response to organic substance GO:0010033 9.71 CASP3 CDH1 CDKN1A PTEN
10 branching involved in ureteric bud morphogenesis GO:0001658 9.7 CTNNB1 ILK PAX8
11 protein kinase B signaling GO:0043491 9.65 ILK PIK3CA PTEN
12 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.63 ILK MIR19A PAX8
13 hormone biosynthetic process GO:0042446 9.62 TG TPO
14 response to arsenic-containing substance GO:0046685 9.61 CDKN1A PTEN
15 negative regulation of sprouting angiogenesis GO:1903671 9.61 MIR18A MIR19A MIR34C
16 regulation of calcium ion import GO:0090279 9.59 CTNNB1 EGF
17 regulation of protein localization to cell surface GO:2000008 9.58 CTNNB1 EGF
18 regulation of axon regeneration GO:0048679 9.58 BRAF PTEN
19 cellular response to indole-3-methanol GO:0071681 9.55 CDH1 CTNNB1
20 signal transduction by p53 class mediator GO:0072331 9.54 CDKN1A TP53
21 replicative senescence GO:0090399 9.43 CDKN1A TERT TP53
22 entry of bacterium into host cell GO:0035635 9.33 CDH1 CTNNB1 MET
23 negative regulation of apoptotic process GO:0043066 9.32 BRAF CASP3 CDKN1A CTNNB1 ILK MET
24 thyroid gland development GO:0030878 9.26 BRAF NKX2-1 PAX8 TG

Molecular functions related to Anaplastic Thyroid Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.35 CDKN1A CTNNB1 ILK PTEN TP53
2 protein phosphatase binding GO:0019903 9.33 CTNNB1 MET TP53
3 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.26 CASP3 CDKN1A
4 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.8 EGF MET PIK3CA

Sources for Anaplastic Thyroid Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....